• Immix Biopharma investor presentation highlighted NXC-201, a BCMA-targeted CAR-T program positioned for relapsed or refractory AL amyloidosis, where it estimates about 38,500 patients in US lack an FDA-approved treatment option.
• Clinical data referenced from ASH 2025 showed a 75% complete response rate for NXC-201 in relapsed or refractory AL amyloidosis, versus 0%-10% complete response rates cited for current investigator’s-choice regimens.
• Reimbursement benchmark for BCMA CAR-T was cited at about $422,000, framing a multi-billion-dollar commercial opportunity based on the estimated patient pool.
• Development timeline pointed to NXC-201 NEXICART-2 as a US trial with registrational design, with final readout targeted for a Q3 topline and a commercial launch plan in 1H 2027.
• Presentation also outlined potential expansion into immune-mediated diseases beyond AL amyloidosis, with neurology and rheumatology among highlighted areas.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immix Biopharma Inc. published the original content used to generate this news brief on May 03, 2026, and is solely responsible for the information contained therein.